From Wikipedia, the free encyclopedia
  (Redirected from Levocetrizine dihydrochloride)
Jump to navigation Jump to search
Levocetirizine structure 2.svg
Ball-and-stick model of the levocetirizine molecule
Clinical data
Trade namesXyzal, Levazyr, others
Other namesLevocetirizine dihydrochloride
  • US: B (No risk in non-human studies)
Routes of
By mouth
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: OTC
Pharmacokinetic data
Protein binding90%
MetabolismHepatic 14% CYP3A4
Elimination half-life6 to 10 hours
ExcretionRenal and fecal
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass388.888 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Levocetirizine, sold under the brand name Xyzal among others, is an antihistamine used for the treatment of allergic rhinitis (hay fever) and long term hives of unclear cause.[1] It is less sedating than older antihistamines.[2] It is taken by mouth.[1]

Common side effects include sleepiness, dry mouth, cough, vomiting, and diarrhea.[1] Use in pregnancy appears safe but has not been well studied and use when breastfeeding is of unclear safety.[3] It is classified as a second-generation antihistamine and works by blocking histamine H1-receptors.[4][1]

Levocetirizine was approved for medical use in the United States in 2007.[1] It is available as a generic medication.[2] A month supply in the United Kingdom costs the NHS about 4.50 £ as of 2019.[2] In the United States the wholesale cost of this amount is about US$3.[5] In 2016 it was the 163rd most prescribed medication in the United States with more than 3 million prescriptions.[6]

Medical uses[edit]

Levocetirizine is used for allergy symptoms including watery eyes, runny nose, sneezing, hives, and itching.[7] The manufacturers claim it to be more effective with fewer side effects than previous second-generation drugs; however, there have been no published independent studies supporting these comparative assertions. A study part-funded by the manufacturer UCB concluded it may be more effective than some other second- and third-generation anti-histamines, but did not compare it to cetirizine.[8]

Side effects[edit]

Levocetirizine is called a non-sedating antihistamine as it does not enter the brain in significant amounts, and is therefore unlikely to cause drowsiness. Cardiac safety with repolarization may be better than some other antihistamines, as levocetirizine does not significantly prolong the QT interval in healthy individuals.[9][10][11] However, some people may still experience some slight sleepiness, headache, mouth dryness, lightheadedness, vision problems (mainly blurred vision), palpitations and fatigue.[12]


Levocetirizine is an antihistamine. It acts as an inverse agonist that decreases activity at histamine H1 receptors. This in turn prevents the release of other allergy chemicals and increase the blood supply to the area, and provides relief from the typical symptoms of hay fever.


Chemically, levocetirizine is the active levorotary enantiomer of cetirizine, also called the l-enantiomer of cetirizine. It is a member of the diphenylmethylpiperazine group of antihistamines.


Levocetirizine was first launched in 2001 by Belgian pharmaceutical company UCB.

Society and culture[edit]


On 31 January 2017, the Food and Drug Administration approved an over-the-counter version.[13] Although the drug was authorized by the FDA in 2007, it was already available in most European countries. Like many new drugs it entered the market at a higher price than currently available third and second generation antihistamines. In India, one form of the drug is available as Crohist MK tablets and syrup, a formulation of levocetirizine hydrochloride and montelukast. In India, Crohist MK is a Schedule 'H' drug and may only be prescribed by a registered medical practitioner.

Brand names[edit]

Different brands (Actavis, Glenmark, UCB) Levocetirizine tablets and oral solution.

Levocetirizine is sold under the following brand names:

  • Xyzal /ˈzˌzɑːl/ in Australia, Austria, Bulgaria, Croatia, Czech Republic, Finland, France, India, Ireland (also Rinozal), Italy, Lithuania, Netherlands, Poland, Portugal, Romania, Taiwan, Thailand, Turkey, The Philippines, Serbia, Singapore, Slovakia, Slovenia, South Africa and UK. On May 25, 2007, the United States Food and Drug Administration approved Xyzal, where it is co-marketed by Sanofi-Aventis.
  • Xusal in Germany, Mexico
  • Xozal in Greece
  • Xazal in Spain
  • In Hungary it is marketed as Zilola (made by Richter Gedeon), Histisynt (Actavis) and Xyzal (UCB).
  • In Bangladesh, levocetirizine available as Alcet by Healthcare pharma, Curin by Beximco pharma and Seasonix by Incepta.
  • In India, levocetirizine is marketed by GlaxoSmithKline under the brand name Vozet. Torrent Pharma launched UVNIL for the rural market. Kaptab Pharmaceuticals markets a mouth dissolving form in India.
  • In Pakistan levocetirizine was first launched in a liquid formulation by Novartis Consumer Health Division under the name of T-Day Syrup.
  • In Nepal levocetirizine is available in tablets with the brand name Curin manufactured by Beximco Pharma.[14]
  • In the Czech Republic, it is also marketed as Zenaro as a prescription drug and is made by Zentiva (Sanofi).
  • In Chile, it is marketed by GSK as Xuzal and as Zival and by Laboratorio Saval.


  1. ^ a b c d e "Levocetirizine Dihydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 22 March 2019.
  2. ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 280–281. ISBN 9780857113382.
  3. ^ "Levocetirizine Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
  4. ^ Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CC, Schuller D, Spector SL, Tilles SA (August 2008). "The diagnosis and management of rhinitis: an updated practice parameter". The Journal of Allergy and Clinical Immunology. 122 (2 Suppl): S1–84. doi:10.1016/j.jaci.2008.06.003. PMID 18662584.
  5. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
  6. ^ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
  7. ^ "Levocetirizine Oral". WebMD.
  8. ^ Grant JA, Riethuisen JM, Moulaert B, DeVos C (February 2002). "A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects". Annals of Allergy, Asthma & Immunology. 88 (2): 190–7. doi:10.1016/S1081-1206(10)61995-3. PMID 11868924.
  9. ^ Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis A (November 2007). "Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study". European Journal of Clinical Pharmacology. 63 (11): 1011–7. doi:10.1007/s00228-007-0366-5. PMID 17891537.
  10. ^ "Cetirizine and loratadine: minimal risk of QT prolongation". Prescrire International. 19 (105): 26–8. February 2010. PMID 20455340.
  11. ^ Poluzzi E, Raschi E, Godman B, Koci A, Moretti U, Kalaba M, Wettermark B, Sturkenboom M, De Ponti F (2015). "Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe". PLOS ONE. 10 (3): e0119551. Bibcode:2015PLoSO..1019551P. doi:10.1371/journal.pone.0119551. PMC 4364720. PMID 25785934.
  12. ^ XOZAL technical specifications booklet.
  13. ^ "Prescription to Over-the-Counter (OTC) Switch List". Retrieved February 9, 2017.
  14. ^ "Curin". Archived from the original on October 22, 2012. Retrieved August 29, 2012.

External links[edit]